HR 1862 107th Congress House Health Administrative procedure Administrative remedies Civil actions and liability Commerce Competition Congress Congressional reporting requirements Consent decrees Department of Health and Human Services Drug approvals Drug industry Generic drugs Government Operations and Politics Government paperwork Governmental investigations Intellectual property Judicial opinions Law Patents

Greater Access to Affordable Pharmaceuticals Act of 2001

Introduced: May 16, 2001 See on congress.gov

Everywhere this bill has been 4 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

May 7, 2002

Sponsor introductory remarks on measure. (CR H2110)

Jun 1, 2001

Referred to the Subcommittee on Health.

May 16, 2001

Referred to the House Committee on Energy and Commerce.

May 16, 2001

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Greater Access to Affordable Pharmaceuticals Act of 2001 - Amends the Federal Food, Drug, and Cosmetic Act to provide for an accelerated date of approval for a generic drug application.

Allows a drug to be considered a bioequivalent to a listed drug if the effects of such drug and the listed drug do not show a significant difference based on certain tests or studies.

Sets forth requirements concerning the filing of a citizen petition review.

Revises provisions concerning: (1) abbreviated new drug applications and new drug applications with respect to the time required for approval and the certification that a patent is invalid or will not be infringed; and (2) filing an application.

Requires a report concerning the extent to which this Act has: (1) has enabled products to come to market in a fair and expeditious manner, consistent with the rights of patent owners under intellectual property law; and (2) has promoted lower prices of drugs and greater access to drugs through price competition..

What's happening now May 7, 2002

Sponsor introductory remarks on measure. (CR H2110)

Related & companion bills 2

Bill text 1 version

Introduced in House Formatted Text PDF

Source documents hosted by congress.gov.

Committees of jurisdiction 2

Energy and Commerce Committee
House of Representatives
Health Subcommittee
House of Representatives · subcommittee of Energy and Commerce Committee

Cosponsors 10

Baldwin, Tammy

Wisconsin · Sep 24, 2002

Schiff, Adam B.

California · Sep 24, 2002

Thune, John

South Dakota · Jun 4, 2002

Norton, Eleanor Holmes

District of Columbia · May 22, 2002

DeLauro, Rosa L.

Connecticut · Apr 10, 2002

Nadler, Jerrold

New York · Feb 13, 2002

McGovern, James P.

Massachusetts · Jun 7, 2001

Kaptur, Marcy

Ohio · May 16, 2001

Pallone, Frank

New Jersey · May 16, 2001

Sanders, Bernard

Vermont · May 16, 2001

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001. 107th Congress. Open America. https://openamerica.io/bill/107-HR-1862/

MLA

"H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-HR-1862/.

Bluebook (legal)

H.R. 1862, 107th Cong. (2026), https://openamerica.io/bill/107-HR-1862/.

Markdown link

[H.R. 1862: Greater Access to Affordable Pharmaceuticals Act of 2001](https://openamerica.io/bill/107-HR-1862/)